Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SurroMed presses on with cancer diagnostics:

This article was originally published in Clinica

Executive Summary

Biomarker company SurroMed has teamed up with the Comprehensive Cancer Center of Wake Forest University to develop novel diagnostics in prostate and renal cell cancer. The collaboration will involve a portion of the cancer targets that the Mountain View, California firm acquired in a transaction announced earlier this year with the company PPD, a provider of discovery and development services and products for pharmaceutical and biotechnology companies. "This is the first step in our programme to develop novel cancer diagnostics based on differential protein and metabolite profiling," said Gordon Ringold, SurroMed's CEO and chairman.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT064060

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel